PHMR

England

Scotland

France

Germany

New HTA Decisions in France

December 2021

Drug name

TECENTRIQ® (atezolizumab)

Company

Rock Pharma

Decision date

17/11/2021

View source

Our experience

About PHMR

Therapeutic area

Cancer

Therapeutic sub area

Cancer: general and other

Official notice date

14/12/2021

Reimbursement %

Decision (SMR) 
Moderate 
Decision (ASMR) 
No improvement (V)
Indication
TECENTRIQ 840 mg is indicated in combination with bevacizumab, paclitaxel and carboplatin, for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours do not have EGFR mutations or ALK rearrangements.

Decision (SMR) 
Insufficient to justify reimbursement 
Decision (ASMR) 
Unspecified
Indication
After failure of appropriate targeted therapies

Decision Type

Extension of indication

Summary

Considering the condition is life-threatening, the good benefit-risk profile of TECENTRIQ®, the alternatives available, the uncertain place of TECENTRIQ® in the therapeutic strategy, and the unlikely impact of TECENTRIQ® on public health, the committee considered the actual benefit of TECENTRIQ® to be ‘moderate’ in the first indication and ‘insufficient to justify reimbursement’ in the second indication of the Marketing Authorisation.

About PHMR

Our experience